Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector - Results For Fourth Quarter And Full Year 2016
2/28/2017
-
Nordic Nanovector: Invitation To Fourth Quarter And Full Year 2016 Results Presentation And Webcast
2/22/2017
-
Nordic Nanovector: Share Options Granted, Including Options To Primary Insiders
2/2/2017
-
Nordic Nanovector: Share Capital Increase Registered
2/2/2017
-
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insiders
12/9/2016
-
Nordic Nanovector: Betalutin In Combination With Rituximab Demonstrates Synergistic Anti-Tumour Effect In Preclinical Non-Hodgkin Lymphoma Model
12/6/2016
-
Nordic Nanovector: Single-Dose Betalutin Shows Promising Efficacy, Improved Duration Of Response And Favourable Safety In Relapsed NHL Patients
12/5/2016
-
Nordic Nanovector– Results For Third Quarter 2016
11/23/2016
-
Nordic Nanovector Appoints Lisa Rojkjaer, MD As Chief Medical Officer
11/15/2016
-
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin
11/4/2016
-
Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December
11/3/2016
-
Nordic Nanovector: Results From Preclinical Studies Of Betalutin In Combination With Rituximab In Non-Hodgkin Lymphoma Model To Be Presented At American Society of Hematology
11/3/2016
-
Nordic Nanovector And Heidelberg Pharma Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias
10/26/2016
-
Nordic Nanovector: Extraordinary General Meeting Held
10/12/2016
-
Nordic Nanovector Announces The Appointment Of Joanna Horobin, MD As Non-Executive Board Director
10/12/2016
-
Nordic Nanovector And LegoChem Biosciences Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCS) Targeting Leukemias
10/10/2016
-
Nordic Nanovector – Changes To The Board Of Directors And Notice Of Extraordinary General Meeting
9/21/2016
-
Nordic Nanovector – Notification Of Share Capital Increase
9/13/2016
-
Nordic Nanovector: Lilotomab Pre-Dosing Of NHL Patients Before Betalutin Therapy Lowers Hematological Toxicity With No Reduction In The Tumor Absorbed Radiation Dose
9/6/2016
-
Nordic Nanovector - Financial Calendar
8/31/2016